Page 11 - Junshi Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Junshi Bioscience and Hikma expand cancer treatment to Middle East and North Africa

Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region

United statesJunshi bioscienceSoutheast asiaJunshi biosciencesMiddle east

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoSheng yaoJunshi bioscienceMarek ciszewskiJodi sieversJunshi biosciencesTheresa lavalleeCoherus biosciencesZhi liDevelopment officerExchange commission onIr teamCoherus biosciences incDrug administrationExchange commission

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated

United arab emiratesUnited statesUnited kingdomJunshi bioscienceJunshi biosciencesZhi liMazen darwazehIr teamDrug administrationRegulatory agencyNational reimbursement drug listEuropean medicines agencyPr teamHikma pharmaceuticalsShanghai junshi biosciences co ltdMiddle east

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

Investegate announcements from Junshi Biosciences, Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

United arab emiratesUnited statesUnited kingdomSan franciscoJunshi bioscienceJunshi biosciencesZhi liMazen darwazehIr teamDrug administrationRegulatory agencyNational reimbursement drug listEuropean medicines agencyPr teamInstitute of microbiology the chinese academyHikma pharmaceuticals

Junshi Biosciences and Hikma Sign Exclusive Licensing

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading.

United arab emiratesUnited statesUnited kingdomSan franciscoJunshi bioscienceJunshi biosciencesZhi liMazen darwazehIr teamDrug administrationRegulatory agencyNational reimbursement drug listEuropean medicines agencyPr teamInstitute of microbiology the chinese academyHikma pharmaceuticals